Background--We investigated national trends in volume and outcomes of percutaneous coronary angioplasty (PCI), coronary artery bypass grafting (CABG), and ischemic heart disease-related mortality in Israel.
I
schemic heart disease (IHD) remains among the leading causes of mortality around the globe.
1, 2 The treatment modalities available for patients with IHD include medical management (optimal medical therapy) and coronary revascularization performed either percutaneously (percutaneous coronary intervention [PCI] ) or surgically (coronary artery bypass grafting [CABG] ). The choice among the various options for the individual patient is influenced patient, physician, and institutional factors. Patient factors include the clinical scenario, ie, the acuity, type and severity of symptoms, comorbidities, and coronary anatomy. Physicianrelated factors include specialty, experience, expertise, and natural bias. Institutional factors consist of availability of infrastructure such as cardiac catheterization laboratory and cardiac surgery programs, as well as institutional policies with regards to evidence-based medicine and cost-effective practice.
3, 4 The guidelines for treatment of IHD developed by the various cardiovascular professional societies provide clinicians with a useful tool in selecting the optimal treatment for the individual patient. 5 More recently, appropriate use criteria were defined and updated in an effort to reduce the impact of physician bias, to promote the "heart team" concept, and to decrease the impact of institutional financial pressure on clinical decisions. 6 The impact of practice guidelines and appropriateness criteria on actual decision making is a subject of ongoing investigations. 4 Several studies have previously shown marked changes in type, volume, and outcomes of coronary revascularization procedures during the past 2 decades using global, national, or regional data sets. [2] [3] [4] [7] [8] [9] [10] The aim of the present study was to investigate national-level trends in coronary revascularization and IHD-related mortality in Israel.
Methods Data Sources
Using the 9th and 10th revisions of the International Classification of Diseases (ICD-9 and ICD-10) codes, we linked information derived from 5 national data sets: 
IHD-related mortality
Annual rates of IHD-related mortality were obtained from two data sets: the Central Bureau of Statistics and the Ministry of Interior Mortality Reports. The ICD-10 codes used to identify IHD-related mortality were I20 to I25 and I46.0 to 146.9.
Statistical Analysis
Categorical data were expressed as absolute numbers with percentages. Continuous variables were expressed as median and interquartile range (IQR Figure 1 ).
The volume of PCI increased by 9% from 2002 to 2008 (387.4/100 000 to 423.2/100 000) and then steadily declined by 10.5% to 378.5/100 000 in 2014 (P=0.7; Table 1 , Figure 1 ). The volume of CABG decreased by 59% (109.0/100 000 to 45.2/100 000) from 2002 to 2013, leveling off during the last year of the study to 46.3/100 000 (P<0.0001; Table 1, Figure 1 ). Figure 2A ). There was a marked institutional variability with regards to procedural volume and the PCI/CABG ratio ranging from a median of 2.1 (IQR=1.8-2.4) to 9.9 (IQR=7.3-12.3) (Table 2, Figure 2B ). We could not obtain the PCI/CABG ratio for the institutions performing PCI only. Revascularization procedures performed on patients who underwent diagnostic catheterization at an institution with no cardiac surgery program and referred for CABG elsewhere, were counted within the institution performing the CABG. This limitation skewed the institutional PCI/CABG ratio to be lower.
Patient Clinical Profile and Procedural Outcomes
We observed variable trends with respect of associated comorbidities in patients undergoing both types of coronary revascularization procedures (Table 3) . While the prevalence of some of the risk factors such as renal failure, chronic obstructive pulmonary disease and prior myocardial infarction, hypertension, and diabetes mellitus increased, other factors such as peripheral vascular disease declined or remained stable (heart failure).
In-hospital procedural mortality ( Figure 3A ) was higher after CABG and remained stable after both types of revascularization procedures (PCI: 1.2-1.6%, P=0.34; CABG: 3.7-4.3%, P=0.3) during the study period. Length of hospital stay ( Figure 3B ) decreased after PCI from a mean of 4.9AE1.9 days (median 5. 
IHD-Related Mortality
To assess the national rates of IHD-related mortality, we summed the mortality rates after acute ST-or non-STsegment elevation myocardial infarction, other types of acute coronary syndrome, and sudden cardiac death. During the study period, annual IHD-related mortality decreased by 46% (84.6/100 000 to 46/100 000, P<0.0001; Figure 4 ). 
Discussion
The first major observation in our study was a significant decline in the total number of coronary revascularization procedures. This is in line with other reports from the United States, Australia, and the Organization for Economic Cooperation and Development (OECD)-an organization of 35 countries from North and South America, Europe, and Asia with a mission to promote policies that will improve the economic and social well-being [including health] of people around the world.).
2-4,7-10 Three major factors may account for this phenomenon. The first one is the accumulating data that in select groups of patients with IHD, optimal medical treatment yields equivalent, or at times superior, outcomes compared with PCI. 11, 12 The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial randomized 2287 patients with objective evidence of significant myocardial ischemia and coronary disease to optimal medical treatment or PCI. PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy. 11 In a more recent meta-analysis of 100 trials in 95 553 patients with 262 090 patient years, PCI using newer-generation drugeluting stents was associated with a decreased need for revascularization but had no effect on patient survival or adverse cardiac events. In contrast, CABG reduced the risk of death, myocardial infarction, and subsequent myocardial revascularization compared with medical treatment. 12 The second factor is the increasing awareness that objective assessment of the hemodynamic significance of coronary artery stenosis using tests such as functional flow reserve is a key to determine whether any form of revascularization is indicated. 13 The third factor is the introduction of appropriateness criteria for coronary revascularization as a tool to prevent overuse or underuse of PCI. 6 In a study of 2.7 million
PCIs from 766 hospitals, Desai and colleagues 4 showed that adherence to the criteria was associated with a significant decline in the total number of PCIs performed, particularly those deemed inappropriate or with borderline indication. The second major observation in our study was the dramatic shift from CABG to PCI as the revascularization of choice. This is in line with other reports published during the past 2 decades.
2-4,7-10 The marked increase in the national PCI to CABG ratio from 3.6 to 8.5 in the early period of our study reflects a dramatic shift in practice of cardiovascular specialists in Israel. This is among the highest value reported at a regional or national level, and is substantially higher compared with that reported in the United States and Australia and the average OECD rate. 2 On a national level, Spain, France, Estonia, and Korea are countries with a similar or slightly higher PCI/CABG ratio compared with Israel. In the United States, only a few single institutions in New York City reported similar PCI to CABG rates.
2,3,7,14
The widespread adoption of PCI as the coronary revascularization of choice is related to a combination of objective and subjective factors. Compared with CABG, PCI is less invasive, can be performed much faster in urgent or emergent situations, and requires less infrastructure. Introduction of drug-eluting stents, improving catheter and imaging techniques and technologies, and increased experience resulted in an exponential use of PCI as the preferred approach with improved early and mid-term outcomes. However, in recent years, it has become apparent that CABG should remain the revascularization procedure of choice in specific patient populations such as those with diabetes mellitus and those with complex left main disease, 2-vessel disease with proximal left anterior descending coronary artery disease, or severe 3-vessel disease. Five-year data from prospective randomized trials including the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery), BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes), and FREEDOM (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease) trials, large "real-world" registries and meta-analyses showed that in these patient populations, CABG is superior to PCI with regards to midterm survival, incidence of major adverse cardiac events, and rates of repeat revascularization. [15] [16] [17] [18] [19] [20] Despite the unequivocal evidence reflected in professional cardiovascular societies guidelines for revascularization, 5 subjective physician, institutional, and patient factors continue to play a major role in the bias towards a specific type of revascularization procedure. Physician-related factors include unfamiliarity with the most recent data and updated guidelines, operator bias, and conflicts of interest inherent to the setting where the same operator performs the diagnostic and therapeutic procedures. Institutional factors include infrastructure, policies, and financial considerations. Finally, in line with the ethical principle of patient autonomy, patient natural inclination towards a less invasive procedure and culturerelated preferences play a central role. We believe that this array of factors has led to disproportional use of PCI over CABG in Israel, often not in accordance with practice guidelines and appropriateness criteria.
In agreement with other reports, our study showed a wide institutional variation in practice with PCI to CABG ratios ranging from 2.1 to 9.5. [2] [3] [4] 14 This observation suggests that institutional policies, financial pressures, heterogeneous infrastructure, patterns of practice, and cardiology-cardiac surgery level of collaboration play a major role in selecting the type of revascularization procedure. It also underscores the importance of the heart team concept to ensure a more structured, uniform, and nonbiased process. 21 We believe that different levels of implementation of the heart team concept may explain the wide institutional range of PCI to CABG ratio. A unique observation in the present study is the shift of the practice pendulum back towards CABG in the final 3 years of the study. The volume of CABG procedures leveled off and even slightly increased at the same time that PCI procedural volume continued to decline, resulting in a PCI to CABG ratio of 8.2 at the final year of the study. Our study was not designed to investigate the causes of the observed changes in practice. An effective way to examine the cause and effect of such changes in practice would be to establish an IHDspecific (rather than procedural-specific) national clinical database similar to that recently accomplished in the Netherlands. 22 A comprehensive collection of data on the 3 treatment modalities of IHD-optimal medical therapy, PCI and CABG--including long-term outcomes, would be a very powerful tool to investigate these questions. We hypothesize that the accumulating level A data derived from randomized trials involving large numbers of patients with long-term follow-up, familiarity with the appropriate use criteria and current guidelines, and perhaps implementation of the heart team concept in a larger proportion of patients may account for these changes. Our observation is similar to that described by Bangalore and colleagues 23 who assessed the impact of the COURAGE and BARI 2D trials on more than 8.1 million PCIs. The clinical profile of the patients in this study was typical of patients undergoing coronary revascularization in the current era. The procedural mortality of CABG and PCI remained relatively stable, despite the high proportion of patients with significant comorbidities. The raw mortality rates for CABG and PCI are somewhat higher compared withthose reported by the American Society of Thoracic Surgeons and the National Cardiovascular Data Registry. 24, 25 However, it is difficult to compare outcomes without a valid and reliable model of riskadjustment. Furthermore, we reported in-hospital mortality. It has been clearly established that 30-or even 120-day mortality rates are more accurate quality measures. 26, 27 Interestingly, we observed a significant increase in hospital length of stay after CABG and a significant decrease after PCI. The causes of these trends are unclear. We speculate that a change in the risk profile of patients referred for CABG may account for this observation. In line with other reports, over time, patients undergoing CABG in Israel were older, sicker, and have more advanced coronary disease. 8, 25 The length of hospital stay after both procedures were longer compared with those reported by the Society of Thoracic Surgeons and the National Cardiovascular Data Registry. 28 Similar to mortality, it is impossible to reliably compare our outcomes with any benchmark without using validated length-of-stay prediction models. A fundamental difference between Israel and the United States is the discharge destination. The majority of patients in Israel are discharged to home, whereas a significant proportion of patients in the United States are discharged to extended-care facilities. 28, 29 Parallel to the dramatic change in the volume and type of coronary revascularization procedure, we observed a 46% decline in IHD-related mortality in Israel during the study period-from 84.6 per 100 000 to 46 per 100 000. This absolute rate, as well as the steepness of decline are among the best in the OECD, and substantially better compared with the United States. 2 As a result, IHD moved to be the second most common cause of death in Israel, being replaced by cancer. 30 Our study was not designed to assess the causes of the decline in IHD-related mortality. More effective primary and secondary prevention of atherosclerosis including dietary and lifestyle changes, use of statins, angiotensin-converting enzyme inhibitors, and antidiabetic medications, as well as decreasing incidence and mortality after acute myocardial infarction may all account for the marked decline in IHDrelated mortality we observed. For example, the rate of smoking in adults has dropped by %50% since 1980 and is now only 19.7%. 31 Similarly, the 7-day, 30-day, and 1-year mortality rates after acute myocardial infarction in Israel dropped by more than 50% between 2000 and 2011. 32 The relationship between the observed dramatic national changes in coronary revascularization procedural volume and outcomes and IHD mortality remains to be further investigated.
Study Limitations
Our study relied entirely on data derived from 5 administrative data sets using ICD-9 and ICD-10 codes. This methodology is associated with an inherent risk for undercoding or miscoding. In one study comparing the quality of data in an administrative database with that of a clinical, adjudicated clinical state registry, there was a 27.4% disparity in isolated CABG volume and a 9% relative difference in mortality. 33 However, we believe that although the absolute numbers may not be as accurate as a clinical database, the observed trend changes in volume and outcomes are real. Furthermore, cross-checking of data derived from entirely different sources afforded the opportunity for data validation. Using administrative databases rather than comprehensive national clinical PCI and CABG databases limited our ability to risk-adjust the observed procedural outcomes. This limitation prevented a more accurate and fair comparison between the two revascularization modalities, or benchmark the national outcomes against large databases such as the American Society of Thoracic Surgeons or the European Adult Cardiac Surgery Databases.
Conclusions
This study demonstrated a marked decline in the total volume of coronary revascularization procedures in Israel over a period of 13 years. There was a dramatic shift from CABG to PCI in the early phase. This trend has reversed, with the pendulum shifting slightly back towards CABG in the final years of the study. In parallel, we observed a marked improvement in IHD-related mortality. Further studies are indicated to have a better understanding of the causes of these changes and the impact of coronary revascularization on IHD-related mortality in Israel.
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